Postherpetic Neuralgia Postherpetic neuralgia is a complication of shingles, which is caused by the chickenpox (herpes zoster) virus. Signs and symptoms may include pain, sensitivity to light touch, itching and numbness and weakness or paralysis. The predisposing factors include age, people with HIV and Hodgkin’s lymphoma. Treatment includes anticonvulsants, antidepressants and opioid painkillers.
Request for sample @ https://marketreportscenter.com/request-sample/438513
Postherpetic Neuralgia pipeline therapeutics constitutes close to 23 molecules. which approximately 23 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 3, 7 and 1 respectively.
Check Discount on report @ https://marketreportscenter.com/request-discount/438513
latest report Postherpetic Neuralgia – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects.
The report is built using data and information sourced from Our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more details of report, table of content, purchase copy of report visit https://marketreportscenter.com/reports/438513/postherpetic-neuralgia-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center